Sunday, 22 May, 2022
TopicPharmaceutical companies

Topic: Pharmaceutical companies

Pharma firms and diagnostics developers need to unite. They are catalysts for saving lives

Studies of drugs like remdesivir and hydroxychloroquine were underpowered and small, and the results were conflicting and, in many cases, inconclusive.

Molnupiravir helps in faster recovery of mild Covid patients, says Hetero after phase 3 trials

Hyderabad-based pharma company, Hetero, announced promising interim results of phase 3 trials and has approached DCGI for emergency use authorisation for the drug in India.

ZyCoV-D, the made-in-India Covid vaccine by Zydus Cadila, likely to hit markets in June

The Ahmedabad-based pharmaceutical firm plans to begin with manufacturing one crore doses a month. The vaccine is also being tested on adolescents.

Delhi HC asks govt to reply to PIL seeking firms to sell Remdesivir in domestic market

The plea claimed that there are more than 25 companies in India which manufacture the medicine, but only 6 to 8 are permitted to sell it in the domestic market.

Pharma industry warns of Covid drug shortages as raw materials prices surge 200%

Pharma firms say suspension of cargo from China has resulted hoarding, driving up prices of raw materials, seek govt intervention immediately.

After govt move to review remdesivir MRP, pharma firms say will cut it to under Rs 3,500/vial

Remdesivir is one of the most sought-after experimental drugs for the treatment of Covid patients and part of the country’s treatment protocol.

Cipla, Sun Pharma, Lupin on drug price watchdog’s new list of firms ‘overcharging consumers’

NPPA has issued a list of  ‘overcharging cases’ under litigation, which includes matters dating back to 1997 & those where firms have moved court against the allegations.

Why there’s no stopping the spectacular rise of this Indian pharma company

The optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chinese suppliers.

Pharma companies to cut prices of news drugs by 51% to access Chinese market

Patients will only need to pay a small fraction of the cost of these drugs as the lion’s share of the bill will be footed by China’s $373 billion national medical insurance fund.

High demand, strict inspections — how Biden’s presidency could impact India’s pharma sector

US is the biggest market for Indian pharmaceutical companies and Biden's presidency is expected to bring with it some favourbable changes that could have a long-ranging impact.

On Camera


Inflation made luxury cars even more expensive but sales remain in fast lane. See Mercedes

For years, the luxury car market in India was biased towards the entry-level. But today, cars below Rs 40 lakh account for the smallest fraction of sales.

World’s $300 trillion in debt. Here’s what it means for services like health, education

To meet debt payments, at least 100 countries will have to reduce spending on essential services, the IMF estimates.


File photo of a defence personnel armed with a SiG 716 rifle near the Line of Control | Photo: Snehesh Alex Philip | ThePrint

India to ink ‘repeat order’ deal for 73,000 SiG 716 rifles from the US

In February 2019, 72,400 SiG 716 rifles of 7.62 x 51mm calibre were contracted from SIG Sauer Inc, USA, under government's 'Buy (Global) category', through fast track procedure.

Mandir or Masjid? New surveys not needed, just acceptance of truth & move towards reconciliation

That temples were destroyed and mosques built is undisputed history. The past can’t be changed, but we can’t deny the wrongs of the past either before we consider reconciliation.